Antonino de Jesus Francisco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonino de Jesus Francisco has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Bombassaro Masiero
Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre, RS, Brazil
1 shared publication - Bianca Collin
Department of Medicine, Hospital Santa Casa, São José dos Campos, SP, Brazil
1 shared publication - Capela António Pascoal
Faculty of Medicine, Agostinho Neto University, P.O. Box 815, Luanda, Angola
1 shared publication - Clara de Andrade Pontual Peres
Universidade de Pernambuco Department of Medicine Recife Pernambuco Brazil Department of Medicine, Universidade de Pernambuco, Recife, Pernambuco, Brazil
1 shared publication - Gabriel Barcellos
Department of Medicine, Faculdade de Ciências Médicas, São José dos Campos, SP, Brazil
1 shared publication - Gabriel Lenz
Internal Medicine, AdventHealth, Orlando, FL
1 shared publication
Latest Publications
- 2 June 2026
- Published by Elsevier in Surgical Oncology
- Vol. 67, 102463
Molecular subtypes and lymph-node metastasis in endometrial cancer: An updated systematic review and meta-analysis
- 2 June 2026
- Published by Elsevier in Surgical Oncology
- Vol. 67, 102463
Molecular subtypes and lymph-node metastasis in endometrial cancer: An updated systematic review and meta-analysis
- Open Access
- 1 January 2026
- Vol. 41 (1)
Mid-term Outcomes of Transcatheter Aortic Valve Replacement vs. Surgical Aortic Valve Replacement in Low-to-Moderate Risk Patients with Severe Aortic Stenosis: A Systematic Review and Meta-analysis.
Several clinical trials have demonstrated the non-inferiority of transcatheter aortic valve replacement compared with surgical aortic valve replacement in patients with severe aortic stenosis and low to intermediate surgical risk. However, mid-term results are still contentious. We performed this meta-analysis to compare the safety and efficacy of transcatheter vs. surgical aortic valve replacement in the mid-term in patients with aortic stenosis at low to moderate surgical risk. We searched Embase, PubMed®, and Cochrane databases for randomized clinical trials that compared transcatheter with surgical aortic valve replacement in patients with symptomatic severe aortic stenosis with a follow-up of at least four years. Outcomes of interest were all-cause mortality and disabling stroke. We included six randomized clinical trials encompassing 6,444 patients with severe aortic stenosis, of whom 3,282 (50.9%) underwent transcatheter aortic valve replacement. There was no difference in all-cause mortality (risk ratio [RR] 1.08; 95% confidence interval [CI] 0.94 - 1.25; P = 0.30) and disabling stroke (RR 0.95; 95% CI 0.75 - 1.21; P = 0.67) between groups. In the subgroup analysis, five-year mortality (RR 1.28; 95% CI 1.10 - 1.49) was higher in the transcatheter group. The new pacemaker implantation (RR 2.22; 95% CI 1.42 - 3.45) rate was higher in the transcatheter group. However, the new atrial fibrillation (RR 0.40; 95% CI 0.31 - 0.52) rate was higher in the surgical group. Mid-term mortality and disabling stroke rates in patients with severe aortic stenosis treated with either transcatheter or surgical aortic valve replacement were similar.
- 1 January 2026
- Vol. 41 (1)
Open AccessMid-term Outcomes of Transcatheter Aortic Valve Replacement vs. Surgical Aortic Valve Replacement in Low-to-Moderate Risk Patients with Severe Aortic Stenosis: A Systematic Review and Meta-analysis.
Several clinical trials have demonstrated the non-inferiority of transcatheter aortic valve replacement compared with surgical aortic valve replacement in patients with severe aortic stenosis and low to intermediate surgical risk. However, mid-term results are still contentious. We performed this meta-analysis to compare the safety and efficacy of transcatheter vs. surgical aortic valve replacement in the mid-term in patients with aortic stenosis at low to moderate surgical risk. We searched Embase, PubMed®, and Cochrane databases for randomized clinical trials that compared transcatheter with surgical aortic valve replacement in patients with symptomatic severe aortic stenosis with a follow-up of at least four years. Outcomes of interest were all-cause mortality and disabling stroke. We included six randomized clinical trials encompassing 6,444 patients with severe aortic stenosis, of whom 3,282 (50.9%) underwent transcatheter aortic valve replacement. There was no difference in all-cause mortality (risk ratio [RR] 1.08; 95% confidence interval [CI] 0.94 - 1.25; P = 0.30) and disabling stroke (RR 0.95; 95% CI 0.75 - 1.21; P = 0.67) between groups. In the subgroup analysis, five-year mortality (RR 1.28; 95% CI 1.10 - 1.49) was higher in the transcatheter group. The new pacemaker implantation (RR 2.22; 95% CI 1.42 - 3.45) rate was higher in the transcatheter group. However, the new atrial fibrillation (RR 0.40; 95% CI 0.31 - 0.52) rate was higher in the surgical group. Mid-term mortality and disabling stroke rates in patients with severe aortic stenosis treated with either transcatheter or surgical aortic valve replacement were similar.